Highly Active Antiretroviral Therapy News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

HAART Mostly Cardioprotective in Kids with HIV (CME/CE)
(MedPage Today) -- But left ventricular contractility declined with increasing follow-up (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 23, 2017 Category: Infectious Diseases Source Type: news

Does HAART Contribute to Syphilis Incidence? Does HAART Contribute to Syphilis Incidence?
A new review examines the possible role HAART may have in the increase of syphilis cases due to susceptibility to infection with T. pallidum.Sexually Transmitted Infections (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 16, 2017 Category: Consumer Health News Tags: Infectious Diseases Journal Article Source Type: news

Which Cancers Secondary to Kaposi Sarcoma Are Emerging in the HAART Era? Which Cancers Secondary to Kaposi Sarcoma Are Emerging in the HAART Era?
Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

BioStable Science & Engineering wins FDA nod for Haart 200 aortic annuloplasty device
Cardiovascular device developer BioStable Science & Engineering said today it won FDA clearance for its Haart 200 aortic annuloplasty device, touting it as the 1st and only such device designed specifically for bicuspid aortic valve repairs. The Austin, Texas-based company’s Haart 200 aortic annuloplasty device is intended for valve repairs in patients with aortic valve insufficiency due to the congenital bicuspid aortic valve malformation in which the aortic valve forms with only 2 functional valve leaflets instead of 3. Bicuspid aortic valve malformations affect up to 2% of the population and carry a significa...
Source: Mass Device - August 15, 2017 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves BioStable Science & Engineering Source Type: news

MassDevice.com +5 | The top 5 medtech stories for June 14, 2017
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry. Get this in your inbox everyday by subscribing to our newsletters. 5. BioStable Science & Engineering begins limited release of Haart 300 annuloplasty device Cardiovascular device developer BioStable Science & Engineering said today it began a limited launch ofits HAART 300 aortic annulop...
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: MassDevice Tags: News Well Plus 5 Source Type: news

BioStable Science & Engineering begins limited release of Haart 300 annuloplasty device
Cardiovascular device developer BioStable Science & Engineering said today it began a limited launch of its HAART 300 aortic annuloplasty device, with the 1st commercial procedure being performed at the West Virginia University Heart and Vascular Institute. The 1st procedure was performed by Dr. Lawrence Wei, Dr. Vinay Badhwar and Dr. J. Rankin, according to the Austin, Texas-based company. “The novel sizing method and simple, quick implantation technique for the HAART 300 aortic annuloplasty device help to standardize the overall repair procedure. Internal annuloplasty has significant advantages over existing ...
Source: Mass Device - June 14, 2017 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Vascular BioStable Science & Engineering Source Type: news

BioStable Science & Eng wins FDA nod for Haart 300 aortic annuloplasty device
Cardiovascular device developer BioStable Science & Engineering said yesterday it won FDA 510(k) clearance for its Haart 300 aortic annuloplasty device. The Austin, Texas-based company touted the Haart 300 as the 1st commercially available internal annuloplasty device designed for aortic valve repair, expected to be available to select US heart centers this summer. “We are very grateful for the cooperation between the BioStable management team and FDA that allowed the company to obtain this market clearance earlier than anticipated, and we look forward to the Haart 300 Aortic Annuloplasty Device being availab...
Source: Mass Device - March 23, 2017 Category: Medical Equipment Authors: Fink Densford Tags: 510(k) Cardiac Implants Cardiovascular Food & Drug Administration (FDA) Regulatory/Compliance Replacement Heart Valves BioStable Science & Engineering Source Type: news

BioStable Science and Engineering Announces FDA Clearance of the HAART(TM) 300 Aortic Annuloplasty Device
AUSTIN, Texas--(Healthcare Sales & Marketing Network)--BioStable Science & Engineering, Inc. announced today it has received FDA market clearance for the HAART 300 Aortic Annuloplasty Device, the first commercially available internal annuloplasty device de... Devices, Cardiology, FDA BioStable Science & Engineering, HAART 300, Aortic Annuloplasty, aortic valve (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2017 Category: Pharmaceuticals Source Type: news

HIV treatment makes patients MORE susceptible to syphilis
HAART - a drug treatment used for HIV infection - might be the reason behind rising rates of syphilis, a new study warns. Rates are 107 times higher in gay/bisexual men. (Source: the Mail online | Health)
Source: the Mail online | Health - January 17, 2017 Category: Consumer Health News Source Type: news

AIDS and Cancer Specimen Resource Young Investigator Pilot Award (2017)
The 2017 AIDS and Cancer Specimen Resource (ACSR) Pilot Study Award is targeted toward junior investigators and faculty with innovative ideas for translational, clinical, or behavioral-epidemiological HIV-related research that utilizes ACSR ' s annotated biospecimens collected from HIV/AIDS patients and controls from both pre and post-HAART periods. (Source: PHPartners.org)
Source: PHPartners.org - January 5, 2017 Category: Global & Universal Source Type: news

HIV, Highly Active Antiretroviral Therapy and the Heart HIV, Highly Active Antiretroviral Therapy and the Heart
What do we know about the cardiometabolic effects of HAART and the risk of cardiovascular disease among HIV-1 infected patients?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 6, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Active surveillance cost effective for first-line HAART in Namibia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2016 Category: Drugs & Pharmacology Source Type: news

My Apology and a Call to Action on MDR-TB
After a career as a physician in public health I find myself impelled to offer a public apology to quite a few patients, only a fraction of whom I have treated. I have been offering up my apologies to individual patients for a few years, but somehow it doesn't seem to be enough. The situation starts with my description of a particular diagnosis and treatment plan, "Your TB is unfortunately due to a TB germ resistant to the two most powerful drugs for treating TB (INH and rifampin). We call it multi-drug resistant, or MDR-TB. I am confident, with the help of the nurses and other TB clinic staff, that we can cure your TB, bu...
Source: Healthy Living - The Huffington Post - March 23, 2016 Category: Consumer Health News Source Type: news

The role of organic transporters in pharmacokinetics and nephrotoxicity of newer antiviral therapies
(Bentham Science Publishers) Highly active antiretroviral therapy and direct acting antiviral agents are key elementsin the effective pharmacotherapy of human immunodeficiency virus and Hepatitis C virus respectively. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 14, 2016 Category: Biology Source Type: news

BioStable Science & Engineering wins CE Mark for annuloplasty device
Cardiovascular device company BioStable Science & Engineering said today it won CE Mark approval in the European Union for its HAART 300 aortic annuloplasty device designed for aortic valve repair. The Austin, Texas-based company said its HAART 300 is an internal aortic annuloplasty ring designed to replicate the anatomy of the aortic valve and resize, reshape and stabilize the aortic annulus to restoe valve competence and prevent recurrent aortic regurgitation. “In patients with mitral and tricuspid valve disease, valve repair has become the standard of care due to superior outcomes compared to biological or mec...
Source: Mass Device - March 8, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiac Implants Cardiovascular Regulatory/Clearance BioStable Science & Engineering Source Type: news